Compare
SAB Biotherapeutics, Inc. vs Sutro Biopharma, Inc. vs Caribou Biosciences, Inc. vs Aura Biosciences, Inc.
| Latest fiscal year | SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue) | Sutro Biopharma, Inc. STRO | Caribou Biosciences, Inc. CRBU | Aura Biosciences, Inc. AURA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $102.48M | $11.16M | n/a |
| Revenue growth (YoY) | n/a | +65.2% | +11.7% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -154.5% | n/m | n/a |
| Net margin | n/a | -186.5% | n/m | n/a |
| Net income | $13.27M | -$191.09M | -$148.12M | -$106.19M |
| EPS (Diluted) | -$0.79 | -$22.49 | -$1.59 | -$1.76 |
| Operating cash flow | -$44.78M | -$177.23M | -$110.99M | -$84.74M |
| Free cash flow | -$45.71M | n/a | -$112.35M | -$85.19M |
| Cash & equivalents | $10.50M | $58.13M | $12.36M | $59.52M |
| Total assets | $172.81M | $173.83M | $175.37M | $169.43M |
| Total liabilities | $21.32M | $306.28M | $53.19M | $32.52M |
| Shareholders' equity | $151.49M | -$132.45M | $122.17M | $136.91M |
| Return on year-end equity | 8.8% | n/a | -121.2% | -77.6% |
| Shares outstanding | 47.61M | 8.58M | 95.14M | 63.59M |
Revenue, most recent five fiscal years
| Fiscal year | SAB Biotherapeutics, Inc. | Sutro Biopharma, Inc. | Caribou Biosciences, Inc. | Aura Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $102.48M Ended 2025-12-31 | $11.16M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $62.04M Ended 2024-12-31 | $9.99M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $153.73M Ended 2023-12-31 | $34.48M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $67.77M Ended 2022-12-31 | $13.85M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $61.88M Ended 2021-12-31 | $9.60M Ended 2021-12-31 | n/a |